|
|
| Clinical Research As A Delicate Ecosystem | Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors. Entrust that your program is in hands you can rely on, where integrity is paramount, and excellence is the standard. |
|
|
|
|
By A. Daram and N. Kunda, St. John's University | There are limitations to the currently available COVID-19 vaccines. An inhalable dry powder approach offers promising benefits, such as eliminating cold chain requirements, for more widespread immunity. |
|
|
“Holy T7 Polymerase, Batman!” R&D Considerations For Awe-Inspiring xRNA | By AR Welch, Editorial & Community Director, Advancing RNA | It goes without saying we have some ambitious therapeutic goals for linear mRNA and next-gen saRNA and circRNA. However, as my conversation with Koeris explored, we still have a lot of scientific and technical work/innovation ahead of us to make our RNA products “stronger” (in more ways than one). |
|
|
AI & Pharmaceutical Development: WHO Calls For Ethical Framework | By Tim Sandle, Ph.D. | The World Health Organization (WHO) recently released a document titled Benefits and risks of using artificial intelligence for pharmaceutical development and delivery describing the ethical issues and governance considerations for using AI in drug discovery, preclinical development, and clinical trials. |
|
|
|
|
| Demand More From Your Oligo Synthesizer | Article | Cytiva | The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development. |
|
|
| Keys To Successful mRNA Manufacturing | Webinar | MilliporeSigma | How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation? |
|
|
| Can mRNA Disrupt The Biopharma Industry? | White Paper | By A. Boulais and P. Nestola, Sartorius | mRNA has the potential to revolutionize the field of vaccine development. However, it is critical we understand any factors that could impact its successful entry into today’s market. |
|
|
.png){kind=logo}
